Heart failure (HF) is a major health concern because of its increasing prevalence and its human, societal and economic impacts. Integration of the know-how from the team led by Prof. Damien Gruson (UCL - IREC/EDIN and CUSL - Department of laboratory medicine) in neurohormones and the clinical knowledge of the team led by Prof. M. Rousseau (UCL - IREC/CARD and CUSL - Division of cardiology) was key in investigating the value of biomarkers for the prognosis of HF.

The quest received a boost in 2015, however, when it also obtained strengths in laboratory medicine and in vitro diagnosis thanks to a research partnership concluded with DiaSorin, an Italian multinational group specialising in development, production and commercialisation of diagnostic tests in a wide range of clinical areas. As vitamin D deficiency and hyperparathyroidism are common in HF patients, potentially contributing to cardiac remodelling, biomarkers derived from bone and mineral metabolism were assessed.

As a result of the partnership, accurate measurements of the biologically active metabolite of vitamin D (1,25-dihydroxyvitamin D) and its ratios to parathyroid hormone (PTH(1-84)), make it possible to strongly and independently predict cardiovascular mortality in HF.

- December 2015: Research and collaboration agreement
- 2015: Patent (first filing in collaboration with DiaSorin)
- 2011: Research project beginning

Facilitate risk stratification in heart failure by identifying meaningful clinical correlates
DiaSorin & UCL: a win-win collaboration for the world of tomorrow